373P The role of concomitant RAS and BRAF mutations in influencing clinical outcome during BRAF-targeted treatment for metastatic colorectal cancer

A Pretta,S Lonardi,E Lai,G Maddalena,C Manai,F Balconi,A.G Leone,M Scartozzi,C Rasola,M Pozzari,V Pusceddu,F Pietrantonio,R Intini,P Ziranu,F Bardanzellu,S Murgia S Murgia,F Bergamo,M Dettori,M Puzzoni,D Spanu

doi:10.1016/j.annonc.2022.07.511

373P The role of concomitant RAS and BRAF mutations in influencing clinical outcome during BRAF-targeted treatment for metastatic colorectal cancer

A Pretta, S Lonardi + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.511

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

#Treatment For Metastatic Colorectal Cancer #BRAF Mutations + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

RAS and BRAF alterations are both prognostic and predictive factors in metastatic colorectal cancer. Recent literature has described cases of RAS and BRAF mutations (mut) coexistence in colorectal cancer. This association appears to be related to poor median overall survival (mOS), median progression free survival (mPFS) and treatments responses. The aim of this study was to evaluate outcomes in patients (pts) harboring BRAF plus RAS mut.

Full Text